SMN2 and proximal spinal muscular atrophy: Gene therapies approved by the Food and Drug Administration (FDA) for SMA include supplementation of the brain with the WT-SMN1 gene to express the WT-SMN protein and regulate the SMN2 gene (Ogbonmide et al., 2023).